Duality Biotherapeutics (映恩生物) Pre-IPO: Too Early, Too Ambitious
Duality biotherapeutics is looking to raise USD 300m in a Hong Kong listing. We look at its core products and key products, as well as its investor...
760 Views
𝛼SK or SearchENTITY
Duality Biotherapeutics (9606 HK)
Duality Biotherapeutics (9606 HK)
71
Analysis
Health Care • China
Duality Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation antibody-drug conjugates (ADCs) to treat cancer and autoimmune diseases. The company develops a pipeline of ADC candidates, including DB-1303/BNT323 (HER2 ADC), DB-1311/BNT324 (B7-H3 ADC), DB-1310 (HER3 ADC), and DB-1305/BNT325 (TROP2 ADC), for various cancers. Duality Biotherapeutics is headquartered in Shanghai, China, and was founded in 2019.
morex